Author

Javier Gisbert

EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE
EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE

Javier Gisbert  et al.

SIXTH-LINE ERADICATION THERAPY AGAINST HELICOBACTER PYLORI INFECTION: PRELIMINARY DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
SIXTH-LINE ERADICATION THERAPY AGAINST HELICOBACTER PYLORI INFECTION: PRELIMINARY DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Javier Gisbert  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Javier Gisbert  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Javier Gisbert  et al.

Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group
Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group

Javier Gisbert  et al.

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Javier Gisbert  et al.

EVALUATION OF THE ACCURACY OF THE "LIAISON(R) MERIDIAN HELICOBACTER PYLORI SA" STOOL ANTIGEN TEST FOR THE DIAGNOSIS OF H. PYLORI INFECTION: A SPANISH MULTICENTRE STUDY
EVALUATION OF THE ACCURACY OF THE "LIAISON(R) MERIDIAN HELICOBACTER PYLORI SA" STOOL ANTIGEN TEST FOR THE DIAGNOSIS OF H. PYLORI INFECTION: A SPANISH MULTICENTRE STUDY

Javier Gisbert  et al.

CHARACTERISTICS AND MANAGEMENT OF PYODERMA GANGRENOSUM AND ERYTHEMA NODOSUM IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PIONOSO MULTICENTER STUDY
CHARACTERISTICS AND MANAGEMENT OF PYODERMA GANGRENOSUM AND ERYTHEMA NODOSUM IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PIONOSO MULTICENTER STUDY

Javier Gisbert  et al.

EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE
EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE

Javier Gisbert  et al.

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

Javier Gisbert  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Javier Gisbert  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Javier Gisbert  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

Javier Gisbert  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

Javier Gisbert  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

Javier Gisbert  et al.

EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)
EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)

Javier Gisbert  et al.

HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Javier Gisbert  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Javier Gisbert  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Javier Gisbert  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Javier Gisbert  et al.

Item 21 - 40 / 78
1
2
3 4